Siemens Healthineers obtains global rights to distribute the Scopio Labs' digital solutions, Scopio X100 and Scopio X100HT, which provide full-field imaging and an AI-powered Decision Support System with remote viewing capabilities
German medical device company Siemens Healthineers has agreed to distribute Scopio Labs’ full-field digital cell morphology platforms, Scopio X100 and Scopio X100HT.
The imaging platforms are intended for use in the central laboratory, adjacent to haematology analysers to examine patient blood cell samples digitally, in place of a microscope.
The X100HT can offer throughput of up to 40 samples per hour, while the X100 can offer a throughput of up to 15 samples per hour.
Scopio’s two imaging platforms will complement the Siemens Healthineers systems, including the Atellica HEMA 570 and Atellica HEMA 580 Analyzers.
Also, they will provide labs with high-resolution, full-field viewing for peripheral blood specimens and AI-based morphological analysis with remote capabilities.
Siemens Healthineers diagnostics head Sharon Bracken said: “By offering laboratorians access to novel digital hematology technologies in one of the lab’s busiest testing disciplines, we will be providing critical tools to optimize operational workflow and laboratory efficiency, accelerate diagnosis, and improve patient care while addressing reduced resource capacity.
“The alliance between Siemens Healthineers and Scopio Labs is a step forward in delivering automated and digitized solutions that would redefine hematology workflow.”
Traditionally, manual microscopy involves examination of slides, which is time-consuming due to the volume of testing and the scope of analysis required for abnormal patient samples.
When a patient blood sample with abnormalities detected or needing further analysis, a slide is prepared with blood smear and sent to the Scopio imaging platform for digitalisation.
Scopio Labs said that its full-field imaging technology provides both the clinical big picture and the smallest details of a cell at the same time.
Its integrated AI decision support will provide laboratory professionals with a highly efficient way to standardise WBC differentials, RBC blood morphology, and platelet estimations.
Also, the remote review capabilities help laboratory professionals provide fast analyses for their patients while better managing professional resources at their institutions.
Scopio Labs CEO and cofounder Itai Hayut said: “With Siemens Healthineers’ strong focus on data-driven clinical decision-making and our shared mission to innovate and shape the future of hematology, we are excited to include our Full-Field Cell Morphology imaging and analysis platforms as a part of their extensive laboratory diagnostics portfolio.
“This partnership will help accelerate digital workflow transformation in hematology laboratories worldwide to enhance clinical decisions for optimal patient care.”